Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 509

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 509
---

is based on the historical volatility of the Company’s common stock.

F-27

The calculation was based on the following assumptions:

|                          |     | Year Ended December 31, 
                    2023 |     |             2022 |
|:-------------------------|:----|------------------------:|:----|-----------------:|
| Strike price (per share) |     |           $4.00 - $5.98 |     |  $11.40 - $11.66 |
| Risk-free interest rate  |     |           5.24% - 5.41% |     |    1.54% - 4.40% |
| Expected volatility      |     |        60.99% - 176.11% |     | 92.59% - 105.68% |
| Expected term (in years) |     |                     0.5 |     |              0.5 |
| Expected dividend yield  |     |                       — |     |                — |

As of December 31, 2023 and 2022, 659,146 and 492,361 shares of common stock were available for issuance under the 2021 ESPP, respectively. The Company had an outstanding liability of $0.1 million and $76,000 at December 31, 2023 and 2022, respectively, which will be recognized over six months. During the years ended December 31, 2023 and 2022, 77,565 and 27,202 shares were issued under the 2021 ESPP, respectively. 12. Income Taxes The Company recorded no income tax expense for the years ended December 31, 2023 and 2022. The Company continues to maintain a full valuation allowance. A reconciliation of the statutory federal income tax with the provision for income taxes are as follows:

|                                          |     | Year Ended December 31, |  2023 |   |     |     |  2022 |   |
|:-----------------------------------------|:----|:------------------------|------:|:--|:----|:----|------:|:--|
| Federal tax at statutory rate            |     |                         |  21.0 | % |     |     |  21.0 | % |
| State income tax, net of federal benefit |